FOCUSED SESSION 2: WHAT DO WE NEED TO BE SUCCESSFUL? NEW DATA INFRASTRUCTURES, RESOURCES, AND LINKAGES

ANGELA MARIOTTO

NATIONAL CANCER INSTITUTE

SEER-MEDICARE DATA

Plusses


- Population representative
- Complete coverage of services for the fee-for-service population
- Longitudinal
- Includes controls for comparisons
- Detailed SEER cancer diagnosis information

SEER-MEDICARE DATA

Minuses

- Recency
- Age distribution
- Limited clinical information.
- No information on progression
- Limited to one payer
- Complex
- Limitation in estimating patients financial distress/burden

SEER-MEDICARE NEW PRODUCT/S: RELATIONAL DATABASES (LINKED BY PATIENT/TUMOR ID)



FINANCIAL TOXICITY USING COMMERCIALLY AVAILABLE SOURCES

- A pilot using LexisNexis to understand:
 - Potential differential impact of cancer site, stage, age, and insurance status on financial health over time post diagnosis
 - Feasibility of using commercially available sources to quantify financial health

FINANCIAL TOXICITY USING LEXISNEXIS

- This project "piggybacks" on previous SEER-LexisNexis linkage
 - 3M cancer cases linked to LexisNexis addresses starting 2015 and going back to 2002.
- Includes patients diagnosed in Louisiana & Seattle SEER registries between 2014-2016.
- Patients diagnosed with stage 0 or stage I cancers, those whose cancers were diagnosed at time of death and those who survive less than 6 months after diagnosis were excluded

DATA/ATTRIBUTE (2010-2018)

- Identity's estimated annual income
- Severity index based on the type of derogatory record
- Total subprime credit service offer or information requests (ex. shortterm loans and high-rate credit cards) by identity
- Indicates status of most recent bankruptcy filing (Ex. Discharged, Dismissed, Discharge, NA)

DATA/ATTRIBUTE (2010-2018)

- Time since most recently recorded derogatory public record
- Time since most recently filed lien
- Time since most recently released lien
- Time since most recent bankruptcy filing
- Time since most recently recorded eviction

PREVIOUS EXPERIENCE

- We attempted this Pilot with another financial data aggregator: data was of poor quality
 - Data not collected for research purposes
 - There was almost no changes of data over time. E.g. all cancer patients were in the same income group over time.
 - Not clear how the data got updated, (e.g. at different times for different patients)
 - There may have been problems with the linkage
- Preliminary analysis indicates LexisNexis is of better quality. However:
 - Costly
 - Proprietary we don't know how median income or other variables are calculated

FUTURE?

- Will wait results on LexisNexis pilot
- Patients reported outcome?
- Cohorts by cancer site?